Phosphogliv caps. 65mg + 35mg # 50

Release form, composition and packaging

?

Hard gelatin capsules, No. 0, with an orange body and a black lid

the contents of the capsules are granular powder from white with a slightly yellowish tint to light yellow, with a weak specific odor.

1 caps.

phospholipids (lipoid C80) (in terms of the main component - phosphatidylcholine 73-79%) 65 mg

sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) 35 mg

10 pieces.

- contour cell packaging (5) - cardboard packs.

pharmachologic effect

Combined drug. It has membrane stabilizing, hepatoprotective and antiviral effects. Phosphatidylcholine (the active substance of phospholipids) is the main structural element of cell and intracellular membranes, is able to restore their structure and function in case of damage, providing a cytoprotective effect. It normalizes protein and lipid metabolism, prevents the loss of enzymes and other active substances by hepatocytes, restores the detoxifying function of the liver, inhibits the formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis. Glycyrate (glycyrrhizic acid and salts) has an anti-inflammatory effect, inhibits the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, and increasing the activity of natural killer cells.It has a hepatoprotective effect due to antioxidant and membrane stabilizing activity. Potentiates the action of endogenous glucocorticosteroids, providing anti-inflammatory and anti-allergic effects in non-infectious liver damage. In case of skin lesions due to the membrane-stabilizing and anti-inflammatory action of the components, it limits the spread of the process and contributes to the regression of the disease.

Pharmacokinetics

Phosphatidylcholine More than 90% of ingested phospholipids are absorbed from the small intestine. Most of it is cleaved by phospholipase A to 1-acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. Polyunsaturated phosphatidylcholine enters the bloodstream with lymph flow, from where, mainly in the form associated with high density lipoproteins, it enters the liver. Pharmacokinetics in humans was studied using radioactively labeled dilenoleyl phosphatidylcholine - 3H (choline part) and 14C (linoleic acid residue). Cmax 3H is achieved in 6-24 hours, accounting for 19.9% ��of the prescribed dose 14C - after 4-12 hours, accounting for 27.9%. T1 / 2 of the choline component is 66 hours, the linoleic acid residue is 32 hours. In the feces, 2% 3H and 4.5% - 14C are found in urine - 6% 3H and a minimum amount of 14C. Both isotopes are absorbed in the intestine by more than 90%. Glycyrrhizic acid After oral administration in the intestine under the influence of the enzyme β-glucuronidase produced by bacteria of normal microflora, an active metabolite is formed from glycyrrhizic acid, β-glycyrrhizic acid, which is absorbed into the systemic circulation. In the blood, β-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Excretion of? -Glycyrrhetic acid occurs mainly in bile, in residual amounts in urine. According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2 times.Glycyrrhizic acid After oral administration in the intestine under the influence of the enzyme β-glucuronidase produced by bacteria of normal microflora, an active metabolite is formed from glycyrrhizic acid, β-glycyrrhizic acid, which is absorbed into the systemic circulation. In the blood, β-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Excretion of β-glycyrrhetic acid occurs mainly with bile, in residual amounts - with urine. According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2 times.Glycyrrhizic acid After oral administration in the intestine under the influence of the enzyme β-glucuronidase produced by bacteria of normal microflora, an active metabolite is formed from glycyrrhizic acid, β-glycyrrhizic acid, which is absorbed into the systemic circulation. In the blood, β-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Excretion of? -Glycyrrhetic acid occurs mainly in bile, in residual amounts in urine. According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2 times.which is absorbed into the systemic circulation. In the blood, β-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Excretion of? -Glycyrrhetic acid occurs mainly in bile, in residual amounts in urine. According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2 times.which is absorbed into the systemic circulation. In the blood, β-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Excretion of? -Glycyrrhetic acid occurs mainly in bile, in residual amounts in urine. According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2 times.

Indications for use

- fatty liver degeneration (hepatosis)

- other liver damage (alcoholic, toxic, including medicinal)

- as part of the complex therapy of viral hepatitis, liver cirrhosis, and psoriasis.

Contraindications for use

- antiphospholipid syndrome

- pregnancy (data on efficacy and safety are insufficient)

- lactation period (data on efficacy and safety are insufficient)

- children up to age 12

-

Name ENG

PHOSPHOGLIV

Clinical and pharmacological group

Hepatoprotector with immunomodulatory and antiviral effects

ATX code

Drugs for the treatment of liver diseases

Dosage

35mg + 65mg

Structure

Active substances: Phospholipids (Lipoid C 80) (in terms of 100% substance) (main component phosphatidylcholine 73-79%) - 65 mg, sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) - 35 mg.

Excipients: microcrystalline cellulose - 141.2 mg, calcium carbonate - 204.7 mg, calcium stearate - 0.9 mg, talc - 7.7 mg, colloidal silicon dioxide (aerosil) - 5.5 mg, hard gelatin capsules - 96.0 mg [body: sunset yellow dye (E110) - 1.0%, titanium dioxide (E171) - 1.0%, gelatin - up to 100.0%

cap: titanium dioxide (E171) - 0.2%, iron dye black oxide (E172) - 3.5%, gelatin - up to 100.0%].

Indications

fatty liver degeneration (hepatosis)

other liver damage (alcoholic, toxic, including medicinal)

as part of the complex therapy of viral hepatitis, liver cirrhosis, and psoriasis.

Contraindications

antiphospholipid syndrome

pregnancy (data on efficacy and safety are insufficient)

lactation period (data on efficacy and safety are insufficient)

children under 12 years of age

hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other components of the drug.

The drug should be prescribed with caution to patients with portal hypertension, arterial hypertension.

If you have these diseases, you should consult your doctor before starting the drug.

INN / Active ingredient

phospholipids, sodium glycyrrhizinate

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

Specifications

Category

Hepatoprotectors

Scope of the drug

Gastrointestinal tract

Release form

Capsules

Manufacturer country

Russia

Package quantity, pcs

fifty

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Pharmstandard

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Hepatoprotective agent

Anatomical and therapeutic characteristics

A05BA Drugs for the treatment of liver diseases

Dosage form

Capsules

Expiration date in days

1095

Package weight, g

thirty

Mode of application

:

It is taken orally, during meals, without chewing, with a small amount of liquid. < br> < br> The recommended dosing regimen for adults and children over 12 years old is 2 capsules 3 times a day.

The duration of use can be up to 6 months, on average - 3 months.

Dosage (volume) of the substance in the preparation

:

phospholipids (lipoid C80) (in terms of the main component - phosphatidylcholine 73-79%) 65 mg, sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) 35 mg

Information on technical characteristics, delivery set, country of manufacture